Poolbeg Pharma Raises £4.865 Million to Advance Clinical Trials

Poolbeg Pharma Ltd. ( (GB:POLB) ) has provided an update.

Poolbeg Pharma plc has successfully raised £4.865 million through an upsized and oversubscribed BookBuild Offer, with £150,000 conditionally raised from the offer itself. The proceeds will support a Phase 2a clinical trial for POLB 001, targeting cancer immunotherapy-induced Cytokine Release Syndrome, and an oral GLP-1 proof-of-concept trial, extending the company’s cash runway through 2027. This fundraising effort highlights Poolbeg Pharma’s strategic focus on advancing its clinical-stage programs and strengthening its financial position, potentially enhancing its industry standing and providing value to stakeholders.

More about Poolbeg Pharma Ltd.

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity, with the development of an oral encapsulated glucagon-like peptide receptor (GLP-1R) agonist.

Average Trading Volume: 1,046,972

Technical Sentiment Signal: Sell

Find detailed analytics on POLB stock on TipRanks’ Stock Analysis page.